Vital Therapies (VTL) Tops Q2 EPS by 3c

Vital Therapies (NASDAQ: VTL) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33).

Cash and cash equivalents at June 30, 2016, totaled $73.6 million compared to $83.4 million at December 31, 2015. The Company believes its cash position is sufficient to fund the Company into the first quarter of 2018.

For earnings history and earnings-related data on Vital Therapies (VTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M